Agreed, Lantheus do have a sub par product RE prostate cancer therapy. They have been lucky to be first mover RE imaging however once TLX591 hits the market, their demise will be obvious.
IMO
Agreed, Lantheus do have a sub par product RE prostate cancer...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.40 |
Change
-0.510(2.70%) |
Mkt cap ! $6.147B | |||
| Open | High | Low | Value | Volume |
| $18.67 | $18.80 | $18.34 | $20.58M | 1.112M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1596 | $18.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.50 | 1971 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2024 (20 minute delay) ? |
| TLX (ASX) Chart |